Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial

被引：0
|
作者：
Harry Raftopoulos
William Cooper
Erin O’Boyle
Nashat Gabrail
Ralph Boccia
Richard J. Gralla
机构：
[1] Hofstra North Shore-LIJ School of Medicine,Albert Einstein College of Medicine
[2] TFS International,undefined
[3] FibroGen,undefined
[4] Inc.,undefined
[5] Gabrail Cancer Center,undefined
[6] Center for Cancer and Blood Disorders,undefined
[7] Jacobi Medical Center,undefined
来源：
Supportive Care in Cancer | 2015年 / 23卷
关键词：
Cancer; Chemotherapy-induced nausea and vomiting (CINV); Extended-release; Granisetron; Subcutaneous; APF530;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：723 / 732
页数：9
相关论文
共 50 条
  • [1] Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial
    Raftopoulos, Harry
    Cooper, William
    O'Boyle, Erin
    Gabrail, Nashat
    Boccia, Ralph
    Gralla, Richard J.
    SUPPORTIVE CARE IN CANCER, 2015, 23 (03) : 723 - 732
  • [2] Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy
    Boccia, Ralph
    O'Boyle, Erin
    Cooper, William
    BMC CANCER, 2016, 16
  • [3] Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy
    Ralph Boccia
    Erin O’Boyle
    William Cooper
    BMC Cancer, 16
  • [4] A prospective, randomized, double-blind phase 3 trial of extended-release granisetron (APF530) versus palonosetron (PALO) for preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately (MEC) or highly (HEC) emetogenic chemotherapy: Does a reanalysis using newer ASCO emetogenicity criteria affect study conclusions?
    Raftopoulos, Harry
    Boccia, Ralph V.
    Cooper, William
    O'Boyle, Erin
    Gralla, Richard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] APF530: A NOVEL EXTENDED-RELEASE FORMULATION OF GRANISETRON FOR 5-DAY PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV).
    Smith, Carrie
    Smith, Michele
    Holt, Jolee
    ONCOLOGY NURSING FORUM, 2016, 43 (02) : 63 - 64
  • [6] PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF SUSTAINED-RELEASE GRANISETRON (APF530) AND PALONOSETRON IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN CANCER PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY
    Smith, Carrie
    Gabrail, Nashat
    ONCOLOGY NURSING FORUM, 2014, 41 (02) : E97 - E97
  • [7] Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV)
    Grous, J. J.
    Riegel, E.
    Gabrail, N.
    Charu, V.
    Arevalo-Araujo, R.
    Yanagihara, R.
    Nguyen, A.
    Robertson, P.
    Cooper, B.
    O'Boyle, E.
    Barr, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
    Gralla, R
    Lichinitser, M
    Van der Vegt, S
    Sleeboom, H
    Mezger, J
    Peschel, C
    Tonini, G
    Labianca, R
    Macciocchi, A
    Aapro, M
    ANNALS OF ONCOLOGY, 2003, 14 (10) : 1570 - 1577
  • [9] Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study
    Suzuki, K.
    Yamanaka, T.
    Hashimoto, H.
    Shimada, Y.
    Arata, K.
    Matsui, R.
    Goto, K.
    Takiguchi, T.
    Ohyanagi, F.
    Kogure, Y.
    Nogami, N.
    Nakao, M.
    Takeda, K.
    Azuma, K.
    Nagase, S.
    Hayashi, T.
    Fujiwara, K.
    Shimada, T.
    Seki, N.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1601 - 1606
  • [10] Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial
    Weinstein, C.
    Jordan, K.
    Green, S. A.
    Camacho, E.
    Khanani, S.
    Beckford-Brathwaite, E.
    Vallejos, W.
    Liang, L. W.
    Noga, S. J.
    Rapoport, B. L.
    ANNALS OF ONCOLOGY, 2016, 27 (01) : 172 - 178
12345